Corbus Pharmaceuticals Holdings, Inc./$CRBP
1D1W1MYTD1Y5YMAX
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
- Ticker
- $CRBP
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 36
- Headquarters
- Norwood, United States
- Website
- www.corbuspharma.com
CRBP Metrics
BasicAdvanced
$203M
-
-$6.09
-
-
Price and volume
Market cap
$203M
52-week high
$20.56
52-week low
$7.12
Average daily volume
328K
Financial strength
Current ratio
5.714
Quick ratio
5.49
Long term debt to equity
3.193
Total debt to equity
4.171
Profitability
EBITDA (TTM)
-106.678
Management effectiveness
Return on assets (TTM)
-53.00%
Return on equity (TTM)
-95.58%
Valuation
Price to book
1.92
Price to tangible book (TTM)
1.92
Price to free cash flow (TTM)
-2.025
Free cash flow yield (TTM)
-49.38%
Free cash flow per share (TTM)
-5.18
Growth
Earnings per share change (TTM)
28.02%
3-year earnings per share growth (CAGR)
-17.88%
10-year earnings per share growth (CAGR)
-4.39%
CRBP News
AllArticlesVideos
Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near
MarketBeat2 months ago
Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study
MarketBeat3 months ago
Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout
MarketBeat3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.